Ardila MCM, Sánchez VNL, Huapaya LCE, Vallejo LGP

Language: Spanish
References: 18
Page: 628-635
PDF size: 581.90 Kb.

ABSTRACT

Background: a significant increase in the resistance of some antimicrobial periodontopathogens traditionally used as adjuncts in periodontal therapy has been reported.
Objective: to assess the susceptibility of Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis to moxifloxacin and amoxicillin clavulanic acid in patients with chronic periodontitis.
Methods: an observational cross-sectional study of the universe composed of 30 patients with chronic periodontitis was conducted. Microbiological samples processing were performed following protocols described previously. Disk diffusion tests were used to assess the susceptibility of A. actinomycetemcomitans and P. gingivalis against moxifloxacin and amoxicillin clavulanic acid.
Results: P. gingivalis was the most prevalent microorganism in the population studied. The two periodontopathogens grown were highly sensitive to both antimicrobials tested.
Conclusions: A. actinomycetemcomitans and P. gingivalis are highly susceptible to moxifloxacin and amoxicillin clavulanic acid in this population, therefore it is an alternative adjuvant for the treatment of periodontitis.

REFERENCES

1. Veloo AC, van Winkelhoff AJ. Antibiotic susceptibility profiles of anaerobic pathogens in The Netherlands. Anaerobe. 2015 Feb;31:19-24.

2. Veloo AC, Seme K, Raangs E, Rurenga P, Singadji Z, Wekema-Mulder G, et al. Antibiotic susceptibility profiles of oral pathogens. Int J Antimicrob Agents. 2012 Nov;40(5):450-4.

3. Marcinkiewicz J, Strus M, Pasich E. Antibiotic resistance: a dark side of biofilm‑associated chronic infections. Pol Arch Med Wewn. 2013 Jun;123(6):309-13.

4. Ruiz IF. Risk factors: Periodontitis increases risk of a first MI. Nat Rev Cardiol. 2016 Mar;13(3):124.

5. Ardila Medina CM, Martelo-Cadavid JF, Boderth-Acosta G, Ariza-Garcés AA, Guzmán Zuluaga IC. Adjunctive moxifloxacin in the treatment of generalized aggressive periodontitis patients: clinical and microbiological results of a randomized, triple-blind and placebo-controlled clinical trial. J Clin Periodontol. 2015 Feb;42(2):160-8.

6. Jepsen K, Jepsen S. Antibiotics/antimicrobials: systemic and local administration in the therapy of mild to moderately advanced periodontitis. Periodontol 2000. 2016 Jun;71(1):82-112.

7. Makeeva IM, Daurova FY, Byakova SF, Ippolitov EV, Gostev MS, Polikushina AO, et al. Sensitivity of microbial associations of periodontal lesions to antibacterial agents. Stomatologiia (Mosk). 2016;95(3):26-3.

8. Guzmán Zulúaga IC, Grisales Romero H, Ardila Medina CM. Administración sistémica adjunta de moxifloxacina versus ciprofloxacina más metronidazol en el tratamiento de periodontitis crónica con presencia de bacilos entéricos Gram negativos: II. Análisis multinivel. Revista Facultad de Odontología Universidad de Antioquia. 2012;23(2):207-24.

9. Ardila Medina CM, Granada Garcia MI, Guzmán Zuluaga IC. Antibiotic resistance of subgingival species in chronic periodontitis patients. J Periodontal Res. 2010 Aug;45(4):557-63.

10. Holtfreter B, Albandar JM, Dietrich T, Dye BA, Eaton KA, Eke PI, et al. Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the Joint EU/USA Periodontal Epidemiology Working Group. J Clin Periodontol. 2015 May;42(5):407-12.

11. Ambler J, Rennie R, Poupard J, Koeth L, Stass H, Endermann R, et al. Determination of moxifloxacin anaerobic susceptibility breakpoints according to the Clinical and Laboratory Standards Institute guidelines. Diagn Microbiol Infect Dis. 2008 May;61(1):49-57.

12. Doña I, Barrionuevo E, Blanca-Lopez N, Torres MJ, Fernandez TD, Mayorga C, et al. Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J Investig Allergol Clin Immunol. 2014;24(3):143-53.

13. Haffajee AD, Socransky SS, Gunsolley JC. Systemic anti-infective periodontal therapy. A systematic review. Ann Periodontol. 2003 Dec;8(1):115-81.

14. Tsaousoglou P, Nietzsche S, Cachovan G, Sculean A, Eick S. Antibacterial activity of moxifloxacin on bacteria associated with periodontitis within a biofilm. J Med Microbiol. 2014 Feb;63(Pt 2):284-92.

15. Cachovan G, Nergiz I, Thuss U, Siefert HM, Sobottka I, Oral O, et al. Penetration of moxifloxacin into rat mandibular bone and soft tissue. Acta Odontol Scand. 2009;67(3):182-6.

16. Grellmann AP, Sfreddo CS, Maier J, Lenzi TL, Zanatta FB. Systemic antimicrobials adjuvant to periodontal therapy in diabetic subjects: a meta-analysis. J Clin Periodontol. 2016 Mar;43(3):250-60.

17. Kulik EM, Lenkeit K, Chenaux S, Meyer J. Antimicrobial susceptibility of periodontopathogenic bacteria. J Antimicrob Chemother 2008;61(5):1087-91.

18. Valenzuela MT, de Quadros C. Antibiotic resistance in Latin America: a cause for alarm. Vaccine. 2009 Aug 21;27 Suppl 3:C25-8.